Skip to content
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 331340 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 331

    Medicine slug
    clorazepate
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    11
    Source count
    11
    Agreement rate
    1
    Recorded readings
    1. 40 to 50 hours

      Numeric value
      40
      Unit
      hours
      Source records
      11

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 11 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b59a3ab-3dff-4458-a63a-ef0d9e0d996d (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a4b80e69-b7c7-471a-8ce8-4e992808c669 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40074ed8-0799-e3e0-e063-6394a90ad200 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:919cbd07-f587-4005-acff-26213dd1d1fb (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:69451c35-dd9a-4690-8d5e-4dcfa8837620 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11b72861-64c9-4cdc-9289-c7fa9ea23bf6 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d592a27-f4cf-008a-e063-6394a90a2629 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:499a6989-8912-44b7-b1eb-ee8f85ae378f (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb5c9e98-02b2-4c36-b436-25b58fe3c7d5 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ccaf945-0369-3129-e063-6394a90a2740 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e07efe5-29b6-6d1e-661a-f696c4b17f43 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
  2. Projected row 332

    Medicine slug
    clorazepate
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    11
    Source count
    11
    Agreement rate
    1
    Recorded readings
    1. 97 to 98%

      Numeric value
      97
      Unit
      %
      Source records
      11

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 11 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b59a3ab-3dff-4458-a63a-ef0d9e0d996d (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97 to 98%).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a4b80e69-b7c7-471a-8ce8-4e992808c669 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97-98%).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40074ed8-0799-e3e0-e063-6394a90ad200 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97 to 98%).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:919cbd07-f587-4005-acff-26213dd1d1fb (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97-98%).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:69451c35-dd9a-4690-8d5e-4dcfa8837620 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97 to 98%).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11b72861-64c9-4cdc-9289-c7fa9ea23bf6 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97 to 98%).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d592a27-f4cf-008a-e063-6394a90a2629 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97-98%).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:499a6989-8912-44b7-b1eb-ee8f85ae378f (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97 to 98%).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb5c9e98-02b2-4c36-b436-25b58fe3c7d5 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97 to 98%).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ccaf945-0369-3129-e063-6394a90a2740 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97 to 98%).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e07efe5-29b6-6d1e-661a-f696c4b17f43 (opens source in a new tab)

        Clorazepate label

        Version not recorded · Effective date not recorded

        The protein binding of nordiazepam in plasma is high (97 to 98%).
  3. Projected row 333

    Medicine slug
    clozapine
    Compared field
    tMax
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    16
    Source count
    16
    Agreement rate
    0.625
    Recorded readings
    1. 2.5 hours

      Numeric value
      2.5
      Unit
      hours
      Source records
      10

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 10 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5021d643-32d2-4167-b5d8-90870e68a787 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of clozapine 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:90876802-0e3a-44c9-9ff7-1754dfbe736a (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of CLOZARIL 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:883b5d43-0339-7dc1-f775-93791fb9b978 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of clozapine tablets 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d36c298b-7292-46e0-898f-43d3e11c3cf4 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of clozapine 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9db7aefb-f607-4158-a310-181e631bc648 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of clozapine 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c748f8a-73ce-4bd3-aa30-9c66657f06ec (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of clozapine 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25c0c6d5-f7b0-48e4-e054-00144ff8d46c (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of clozapine tablets 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0fa59238-f0a6-4d00-9d8d-df2a43718fc1 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of clozapine tablets 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61fe53d5-ed5c-4e45-9189-709d08d386cb (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of clozapine 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5c8a456-6f3c-4963-b321-4ed746f690e4 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of clozapine tablets 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
    2. 2.3 hours

      Numeric value
      2.3
      Unit
      hours
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:976be6e3-a9db-49c6-9b02-1ab168cf17b1 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following a dosage of 100 mg b.i.d., the average steady-state peak plasma concentration was 413 ng/mL (range: 132-854 ng/mL), occurring at the average of 2.3 hours (range: 1-6 hours) after dosing.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09231d80-6343-4a34-bd5b-100c547fd3c9 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following a dosage of 100 mg twice daily, the average steady-state peak plasma concentration was 413 ng/mL (range: 132 to 854 ng/mL), occurring at the average of 2.3 hours (range: 1 to 6 hours) after dosing.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:caf2d4a6-2a23-4992-a807-560c4204afc4 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following a dosage of 100 mg twice daily, the average steady-state peak plasma concentration was 413 ng/mL (range: 132 to 854 ng/mL), occurring at the average of 2.3 hours (range: 1 to 6 hours) after dosing.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fccf4f7-2e30-4272-9800-225aaef20584 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following a dosage of 100 mg twice daily, the average steady-state peak plasma concentration was 413 ng/mL (range: 132 to 854 ng/mL), occurring at the average of 2.3 hours (range: 1 to 6 hours) after dosing.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9ae4b8e4-d8b1-4f01-bb4c-cd1cea90b219 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following a dosage of 100 mg twice daily, the average steady-state peak plasma concentration was 413 ng/mL (range: 132 to 854 ng/mL), occurring at the average of 2.3 hours (range: 1 to 6 hours) after dosing.
    3. 2.2 hours

      Numeric value
      2.2
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2592c9a8-fd74-4e0d-a895-b07b014cf355 (opens source in a new tab)

        Clozapine label

        Version not recorded · Effective date not recorded

        Following oral administration of 100 mg to 800 mg VERSACLOZ, once daily, the average steady-state peak plasma concentration was 275 ng/mL (range: 105 - 723 ng/mL), occurring at the average of 2.2 hours (range: 1 - 3.5 hours) after dosing.
  4. Projected row 334

    Medicine slug
    cocaine
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings
    1. 3,877 ± 1,266 L

      Numeric value
      3,877
      Unit
      L
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0fb0298f-9756-26e8-e063-6294a90ae8f2 (opens source in a new tab)

        Cocaine label

        Version not recorded · Effective date not recorded

        In studies with COCAINE HYDROCHLORIDE nasal solution, the apparent volume of distribution (Vd/F) of cocaine after intranasal administration is 3,877 ± 1,266 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f897764-fe30-090a-e063-6294a90af106 (opens source in a new tab)

        Cocaine label

        Version not recorded · Effective date not recorded

        In studies with GOPRELTO, the apparent volume of distribution (Vd/F) of cocaine after intranasal administration is 3,877 ± 1,266 L.
  5. Projected row 335

    Medicine slug
    codeine
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings
    1. 7%

      Numeric value
      7
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5819bdf7-300e-45b8-8f3a-447b53656293 (opens source in a new tab)

        Codeine label

        Version not recorded · Effective date not recorded

        Codeine has low plasma protein binding with about 7% to 25% of codeine bound to plasma proteins.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:010905f9-3bcb-4b50-9fe8-a3ad0010f14c (opens source in a new tab)

        Codeine label

        Version not recorded · Effective date not recorded

        Codeine has low plasma protein binding with about 7% to 25% of codeine bound to plasma proteins.
  6. Projected row 336

    Medicine slug
    codeine
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings
    1. 3 to 6 L/kg

      Numeric value
      3
      Unit
      L/kg
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5819bdf7-300e-45b8-8f3a-447b53656293 (opens source in a new tab)

        Codeine label

        Version not recorded · Effective date not recorded

        D i stribution: Codeine has been reported to have an apparent volume of distribution of approximately 3 to 6 L/kg, indicating extensive distribution of the drug into tissues.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:010905f9-3bcb-4b50-9fe8-a3ad0010f14c (opens source in a new tab)

        Codeine label

        Version not recorded · Effective date not recorded

        Distribution: Codeine has been reported to have an apparent volume of distribution of approximately 3 to 6 L/kg, indicating extensive distribution of the drug into tissues.
  7. Projected row 337

    Medicine slug
    colchicine
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    51
    Source count
    50
    Agreement rate
    1
    Recorded readings
    1. 45%

      Numeric value
      45
      Unit
      %
      Source records
      50

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 50 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16d8e0f4-567d-4de1-ac25-6e2527f1d58e (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d010a735-1a20-23fe-e053-2995a90abe0f (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df1dd89a-a1b3-48e8-b0e8-ad71b4cb0c96 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd93a40f-92ab-47ac-9083-b8a7a0b18ad6 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee1583ac-c308-4beb-b602-9ecac4977026 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eb509994-6ecc-4599-b87a-98495fef6129 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14d4be16-d355-4baf-b4cd-4d97d4b2dca0 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cb88c93-54b8-a548-e063-6294a90a94e6 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efe34b7c-0e6e-4aeb-9718-cf9b8e19a302 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ae87893-a065-468e-b8da-f1db86afcaef (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f69b9c6-8c00-45e2-b950-34dc5ae62352 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:467cd83f-d695-4040-9434-10e80b4271da (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of colchicine is reported to be approximately 45%.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1ff526f-e89f-4dca-80b6-653d6bdfd895 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dcf97364-b35f-4bc9-8a92-d3d2e05f47ac (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25307250-c16b-4467-9ad0-e6c752c576bd (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:472ec026-c755-ae02-e063-6394a90af0c6 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b6abc78-b2d6-4949-b109-4c857f37ef12 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16d49c45-5b0a-a7fa-e063-6294a90a7320 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc0e205a-697e-d47e-e053-2995a90a154e (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b414be4e-cd4f-4e7d-bbdd-b406c99c11b6 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72984aa2-6df9-4460-9926-399ffed30e36 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a4284783-fea6-4af2-9a8d-79c929176c05 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:68d4bf2b-8e2c-4621-aa08-463f43e253c3 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb5f9d85-6b81-49f8-bcd6-17b7bfbc10f2 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6adc880-5499-4691-93f3-27c87902d5fc (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11a62c34-db88-4a79-81a1-59b316d41d66 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b280f0dc-b24c-4606-aaf4-0673070d5b64 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94bee24f-d846-4344-bc42-b2eae6b433ba (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a15538ee-d1eb-4118-97c3-53748cea012a (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e5d9488-d9d0-4b37-b535-941d66c3430d (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7daef7e2-888d-4116-81a9-2c02b9ef97ef (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b78d6f7-714b-4e6c-b109-fbcb96d66633 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5cefec2e-1982-4417-8d99-5711231b3933 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9111bbad-b020-44fb-b276-d7853e5acd2c (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f818ffe0-43df-4cc6-bc86-00b2c79b06fc (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5102af58-15b1-1516-e063-6294a90a50e3 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7d013b7-0a67-0953-e053-2a95a90ac47c (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f5e24de-3956-4724-a5d7-fe81dcb07f6e (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19486f52-1c7b-43b8-ba48-0d1a6389fedf (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5c1ceff7-8f00-48cc-8ea4-678106455ff1 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac12e420-9f29-018e-e053-2a95a90ab612 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b310c57c-9192-4dc8-b76f-2c1982941caf (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e7ef16d-262b-4dc0-92d6-7afe4aa21ebd (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85acf34c-06c6-40ea-95f4-060d5de99277 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e7c8f65-4722-4187-9014-8fa81eb5681e (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d83c6ae4-a41c-4b14-94b3-2d93c9aa28d1 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b79a786-3f9e-4dad-aa66-bae5f299b966 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cd5298e-43c6-a8dc-4467-9a3e1ade9307 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50b9c910-49a3-4a57-80f5-dc36c09da4df (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Absolute bioavailability is reported to be approximately 45%.
  8. Projected row 338

    Medicine slug
    colchicine
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    51
    Source count
    18
    Agreement rate
    0.777778
    Recorded readings
    1. 31 h

      Numeric value
      31
      Unit
      hours
      Source records
      14

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 14 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee1583ac-c308-4beb-b602-9ecac4977026 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eb509994-6ecc-4599-b87a-98495fef6129 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cb88c93-54b8-a548-e063-6294a90a94e6 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efe34b7c-0e6e-4aeb-9718-cf9b8e19a302 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:467cd83f-d695-4040-9434-10e80b4271da (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of GLOPERBA in healthy adults is 31 hours (± 6 hours).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1ff526f-e89f-4dca-80b6-653d6bdfd895 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25307250-c16b-4467-9ad0-e6c752c576bd (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:472ec026-c755-ae02-e063-6394a90af0c6 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16d49c45-5b0a-a7fa-e063-6294a90a7320 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb5f9d85-6b81-49f8-bcd6-17b7bfbc10f2 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b280f0dc-b24c-4606-aaf4-0673070d5b64 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f5e24de-3956-4724-a5d7-fe81dcb07f6e (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19486f52-1c7b-43b8-ba48-0d1a6389fedf (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d83c6ae4-a41c-4b14-94b3-2d93c9aa28d1 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).
    2. 18.8 hours

      Numeric value
      18.8
      Unit
      hours
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs. 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hours vs. 4.4 hours) as compared to subjects with FMF and normal renal function [see Dosage and Administration ( 2.5 ), Use in Specific Populations ( 8.6 )] .
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b6abc78-b2d6-4949-b109-4c857f37ef12 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs. 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hours vs. 4.4 hours) as compared to subjects with FMF and normal renal function [see Dosage and Administration ( 2.5 ), Use in Specific Populations ( 8.6 )] .
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6adc880-5499-4691-93f3-27c87902d5fc (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs. 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hours vs. 4.4 hours) as compared to subjects with FMF and normal renal function [see Dose Modification in Renal Impairment (2.5) and Renal Impairment (8.6) ] .
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94bee24f-d846-4344-bc42-b2eae6b433ba (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs. 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hours vs. 4.4 hours) as compared to subjects with FMF and normal renal function [see Dosage and Administration ( 2.5 ), Use in Specific Populations ( 8.6 )] .
  9. Projected row 339

    Medicine slug
    colchicine
    Compared field
    volumeOfDistribution
    Comparison state
    not_comparable
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    • DENOMINATOR_MISMATCH
    Documents examined
    51
    Source count
    50
    Agreement rate
    0.92
    Recorded readings
    1. 5 to 8 L/kg

      Numeric value
      5
      Unit
      L/kg
      Source records
      46

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 46 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16d8e0f4-567d-4de1-ac25-6e2527f1d58e (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d010a735-1a20-23fe-e053-2995a90abe0f (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df1dd89a-a1b3-48e8-b0e8-ad71b4cb0c96 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd93a40f-92ab-47ac-9083-b8a7a0b18ad6 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee1583ac-c308-4beb-b602-9ecac4977026 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eb509994-6ecc-4599-b87a-98495fef6129 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14d4be16-d355-4baf-b4cd-4d97d4b2dca0 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cb88c93-54b8-a548-e063-6294a90a94e6 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efe34b7c-0e6e-4aeb-9718-cf9b8e19a302 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ae87893-a065-468e-b8da-f1db86afcaef (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f69b9c6-8c00-45e2-b950-34dc5ae62352 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1ff526f-e89f-4dca-80b6-653d6bdfd895 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dcf97364-b35f-4bc9-8a92-d3d2e05f47ac (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25307250-c16b-4467-9ad0-e6c752c576bd (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:472ec026-c755-ae02-e063-6394a90af0c6 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16d49c45-5b0a-a7fa-e063-6294a90a7320 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc0e205a-697e-d47e-e053-2995a90a154e (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b414be4e-cd4f-4e7d-bbdd-b406c99c11b6 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72984aa2-6df9-4460-9926-399ffed30e36 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a4284783-fea6-4af2-9a8d-79c929176c05 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:68d4bf2b-8e2c-4621-aa08-463f43e253c3 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb5f9d85-6b81-49f8-bcd6-17b7bfbc10f2 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6adc880-5499-4691-93f3-27c87902d5fc (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11a62c34-db88-4a79-81a1-59b316d41d66 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b280f0dc-b24c-4606-aaf4-0673070d5b64 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a15538ee-d1eb-4118-97c3-53748cea012a (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e5d9488-d9d0-4b37-b535-941d66c3430d (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7daef7e2-888d-4116-81a9-2c02b9ef97ef (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b78d6f7-714b-4e6c-b109-fbcb96d66633 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5cefec2e-1982-4417-8d99-5711231b3933 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9111bbad-b020-44fb-b276-d7853e5acd2c (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f818ffe0-43df-4cc6-bc86-00b2c79b06fc (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5102af58-15b1-1516-e063-6294a90a50e3 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7d013b7-0a67-0953-e053-2a95a90ac47c (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f5e24de-3956-4724-a5d7-fe81dcb07f6e (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution: Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19486f52-1c7b-43b8-ba48-0d1a6389fedf (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5c1ceff7-8f00-48cc-8ea4-678106455ff1 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac12e420-9f29-018e-e053-2a95a90ab612 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b310c57c-9192-4dc8-b76f-2c1982941caf (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e7ef16d-262b-4dc0-92d6-7afe4aa21ebd (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85acf34c-06c6-40ea-95f4-060d5de99277 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e7c8f65-4722-4187-9014-8fa81eb5681e (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d83c6ae4-a41c-4b14-94b3-2d93c9aa28d1 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b79a786-3f9e-4dad-aa66-bae5f299b966 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cd5298e-43c6-a8dc-4467-9a3e1ade9307 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50b9c910-49a3-4a57-80f5-dc36c09da4df (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
    2. 5 L/kg

      Numeric value
      5
      Unit
      L/kg
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8fd7034-5ca2-4a58-b303-7f78ffdf8d76 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 L/kg to 8 L/kg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b6abc78-b2d6-4949-b109-4c857f37ef12 (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 L/kg to 8 L/kg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94bee24f-d846-4344-bc42-b2eae6b433ba (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution in healthy young volunteers is approximately 5 L/kg to 8 L/kg.
    3. 1420 L

      Numeric value
      1,420
      Unit
      L
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:467cd83f-d695-4040-9434-10e80b4271da (opens source in a new tab)

        Colchicine label

        Version not recorded · Effective date not recorded

        h∙ng/mL) 19.90 (4.74) 18.47 (4.29) T max (h) (Min-Max) 1.00 (0.50: 2.00) 2.00 (1.00: 4.00) t 1/2 (h) 31.04 (5.99) 30.54 (5.22) Distribution The mean apparent volume of distribution (Vz/F) of GLOPERBA in healthy adults was approximately 1420 L.
  10. Projected row 340

    Medicine slug
    colistimethate
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings
    1. 2 to 3 hours

      Numeric value
      2
      Unit
      hours
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13dc3525-1879-4bd8-a922-81bc1397d5af (opens source in a new tab)

        Colistimethate label

        Version not recorded · Effective date not recorded

        Serum concentration declined with a half-life of 2 to 3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a335659-03b0-4a2d-9cd4-7dcf7da96fe6 (opens source in a new tab)

        Colistimethate label

        Version not recorded · Effective date not recorded

        Serum concentration declined with a half-life of 2–3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ec7dc90-825c-422e-9f4b-c8ace9d93af5 (opens source in a new tab)

        Colistimethate label

        Version not recorded · Effective date not recorded

        Serum concentration declined with a half-life of 2 to 3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6d6e13e2-dc33-4b7b-84d0-66146a57c552 (opens source in a new tab)

        Colistimethate label

        Version not recorded · Effective date not recorded

        Serum concentration declined with a half-life of 2–3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab241809-0d2f-44ba-829c-26be67ee623f (opens source in a new tab)

        Colistimethate label

        Version not recorded · Effective date not recorded

        Serum concentration declined with a half-life of 2 to 3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf556f89-6373-45cb-b465-d991fde7eab9 (opens source in a new tab)

        Colistimethate label

        Version not recorded · Effective date not recorded

        Serum concentration declined with a half-life of 2 to 3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.

Access

Query or download the projection

GET /api/datasets/source-consensus?limit=10&offset=330

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy